Expand XLO Menu
XLO MENU

XLO Latest Press Releases

-- March 23, 2026 --

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results Globe Newswire 7:30 AM

-- March 17, 2026 --

Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting Globe Newswire 4:45 PM

-- March 12, 2026 --

Xilio Therapeutics Announces 1-for-14 Reverse Stock Split Globe Newswire 8:30 AM

-- March 2, 2026 --

Xilio Therapeutics to Present at the Leerink Partners Global Healthcare Conference Globe Newswire 8:00 AM
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 7:30 AM

-- February 11, 2026 --

Xilio Therapeutics Announces Pricing of Underwritten Offering Globe Newswire 9:34 PM

-- January 8, 2026 --

Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates Globe Newswire 8:30 AM

-- November 13, 2025 --

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results Globe Newswire 7:30 AM

-- November 7, 2025 --

Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting Globe Newswire 9:05 AM
Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting Globe Newswire 9:01 AM

-- November 3, 2025 --

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:30 PM

-- October 30, 2025 --

Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting Globe Newswire 9:01 AM
Market Data Delayed 15 Minutes